ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANI PHARMACEUTICALS INC (ANIP) reports that President and CEO Nikhil Lalwani sold 5,400 shares of common stock on September 15, 2026 at $71.00 per share, for about $383,400 in total proceeds. After this transaction, he directly holds 339,089 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on May 26, 2026.
ANI PHARMACEUTICALS INC (ANIP) received a notice that Nikhil Lalwani plans to sell common stock under Rule 144. The notice covers 5,400 shares of common stock, with an indicated aggregate market value of $380,160.00, against 22,959,488 shares of common stock outstanding on NASDAQ.
The shares to be sold relate to Restricted Stock Awards, with the prospective sale date shown as February 28, 2026. The filing also lists a prior Rule 10b5-1 sale of 5,400 shares of common stock on August 25, 2026 for proceeds of $401,216.22.
ANI PHARMACEUTICALS INC (ANIP) director Jeanne Thoma reported selling 1,000 shares of common stock on September 11, 2026 at $71.53 per share in an open-market or private transaction. After this sale, she directly holds 26,762 shares. The sale was effected under a Rule 10b5-1 trading plan adopted on June 12, 2026.
ANI PHARMACEUTICALS INC (ANIP) insider Meredith Cook, Senior Vice President, General Counsel & Secretary, reported selling 500 shares of common stock on September 14, 2026 at $70.79 per share. After this transaction, she directly holds 73,924 shares of ANI Pharmaceuticals common stock.
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025, indicating the trade was made under a pre-arranged plan.
ANI PHARMACEUTICALS INC (ANIP) has a notice of proposed sale under Rule 144 filed for the account of director Jeanne Thoma. The filing covers the potential sale of 1,000 shares of common stock through Morgan Stanley Smith Barney LLC on or about September 11, 2026, with an indicated aggregate market value of $71,460. The shares to be sold were acquired as Restricted Stock Awards from the issuer on May 22, 2026; shares of common stock outstanding were stated as 22,959,488 for context.
ANI PHARMACEUTICALS INC (ANIP) disclosed that SVP & CFO Stephen P. Carey sold 2,850 shares of common stock on 2026-08-31 at a weighted average price of $72.80 per share, in trades ranging from $71.89 to $73.36, pursuant to a Rule 10b5-1 trading plan. Following this sale, he directly holds 171,843 shares of ANI common stock.
ANI PHARMACEUTICALS INC (symbol: ANIP) is the issuer of record for a Form 4 filing submitted to the SEC.
ANI PHARMACEUTICALS INC (ANIP) filed an initial ownership report for Henry O. Gosebruch, who is identified as a director of the company. This Form 3 does not list any specific equity holdings or report any buy, sell, or derivative transactions in ANI common stock.
ANI PHARMACEUTICALS INC (ANIP) reported that President & CEO Nikhil Lalwani sold 5,400 shares of common stock on August 25, 2026 in an open-market or private transaction at a weighted average price of $74.30 per share, with trades ranging from $73.58 to $74.61. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026. Following this sale, Lalwani directly holds 344,489 shares of ANIP common stock.
ANI PHARMACEUTICALS, INC (symbol ANIP) is named as the issuer in a Rule 144 notice filed for the account of Nikhil S. Lalwani. The notice covers a proposed sale of 5,400 shares of ANI common stock through Morgan Stanley Smith Barney LLC, with an associated value of $400,518.00 based on NASDAQ pricing as of 08/25/2026. The 5,400 shares are reported as having been acquired on 02/28/2026 as an RSA from the issuer. The filing does not indicate additional sales of this class during the preceding three months.